sorafenib has been researched along with gsk2879552 in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (gsk2879552) | Trials (gsk2879552) | Recent Studies (post-2010) (gsk2879552) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 29 | 2 | 26 |
| Protein | Taxonomy | sorafenib (IC50) | gsk2879552 (IC50) |
|---|---|---|---|
| Lysine-specific histone demethylase 1A | Homo sapiens (human) | 0.2407 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C; Chu, X; Geng, J; Han, D; Huang, M; Lei, Z; Wang, C; Wang, L; Wang, T; Wang, Y; Xie, T | 1 |
1 other study(ies) available for sorafenib and gsk2879552
| Article | Year |
|---|---|
Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclopropanes; Drug Resistance, Neoplasm; Histone Demethylases; Humans; Liver Neoplasms; Male; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Niacinamide; Pargyline; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; RNA Interference; Sorafenib; Time Factors; Transfection; Tumor Burden; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2017 |